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Cholesterol gallstone disease is highly prevalent in western countries, particularly in women and some speciﬁc ethnic groups.
The formation of water-insoluble cholesterol crystals is due to a misbalance between the three major lipids present in the bile:
cholesterol, bile salts, and phospholipids. Many proteins implicated in biliary lipid secretion in the liver are regulated by several
transcription factors, including nuclear receptors LXR and FXR. Human and murine genetic, physiological, pathophysiological,
and pharmacological evidence is consistent with the relevance of these nuclear receptors in gallstone formation. In addition, there
is emerging data that also suggests a role for estrogen receptor ESR1 in abnormal cholesterol metabolism leading to gallstone
disease. A better comprehension of the role of nuclear receptor function in gallstone formation may help to design new and more
eﬀective therapeutic strategies for this highly prevalent disease condition.
1.Introduction
Cholesterol gallstone disease (CGD) is one of the most com-
mon digestive disease conditions in both industrialized and
develop-ing western countries. Worldwide CGD prevalence
ranges between 5% and 20% [1], being more common
in women than men in every population that has been
studied[2].Itisparticularlyprevalentinsomespeciﬁcethnic
groups including Mapuche and North American Indians as
well as Chilean and Mexican Hispanics. Among these pop-
ulations, CGD has an earlier onset and reaches prevalence
rates over 50% and 70% in middle age male and women,
respectively. CGD is also a key risk factor for gallbladder
cancer. Therefore, CGD represents a serious burden for
healthcare systems [3, 4].
Some of the pathogenic hallmarks of CGD are increased
biliary cholesterol secretion, in-creased bile acid hydropho-
bicity, cholesterol microcrys-tal formation, growth, and
aggregation with the formation of macroscopic stones in
the gallbladder, and gall-bladder inﬂammation [5–7]. The
primary pathogenic mechanism associated with CGD is a
disrupted balance between the three major lipids present
in bile: cholesterol, bile salts, and phospholipids [8]. Under
physiological conditions, bile cholesterol is kept in solution
by its incorporation into mixed micelles together with phos-
pholipids and bile salts. When either too much cholesterol or
not enough solubilizing bile salt and phospholipid molecules
are secreted, cholesterol comes out of solution and then
crystallizes[9].Inaddition,severalbiliaryproteinshavebeen
described as nucleating factors that may promote cholesterol
crystallization. Among them, there are immunoglobulins M
and G, haptoglobin, α1-acid glycoprotein, aminopeptidase-
N, α1-antichymotrypsin, and mucin. Despite correlative
evidence between biliary levels and/or activity of these
proteins and cholesterol precipitation in in vitro and animal
models,onlymucinseemstohaveapotentialpathogenicrole
in human CGD [9]. Finally, impaired gallbladder motility
is another important factor that contributes to further
growth and aggregation of cholesterol microcrystals into
macroscopic gallstones [7, 10].2 Journal of Lipids
In the hepatocyte, several types of proteins mediate
the traﬃcking of lipids towards the canalicular pole for
biliary secretion. These include multiple lipid transport-
related gene products, lipoprotein receptors, basolateral
lipid transporters, and intracellular lipid binding proteins
as well as canalicular lipid transporters. Especially rele-
vant for biliary lipid secretion and composition is the
activity of ATP-binding-cassette- (ABC-) transport proteins
expressed at the canalicular membrane. Among them, we
can highlight the following ones: ABCB4, the transporter
for phosphatidylcholine [11]; ABCB11, the bile salt export
pump [12]; ABCG5/ABCG8, the obligate heterodimer that
induces biliary cholesterol secretion [13].
Thus, biliary lipid secretion is controlled by a vari-
ety of proteins that mediate lipid uptake, transport, and
metabolism in the liver. Furthermore, the expression of the
genes encoding these proteins is coordinated by a series of
transcriptional factors, including members of the nuclear
receptorsfamily,suchasliverXreceptor(LXR)andfarnesoid
X receptor (FXR) as well as the sterol regulatory element
binding proteins (SREBPs) [14].
2. The Nuclear Receptors
Nuclear receptors (NRs) are a major component of sig-
nal transduction in animals. They are metabolite- and
hormone-sensing transcription factors that translate dietary
or endocrine signals into changes in gene expression.
They have been described as modulators of not only
many hormone activities, but also important nutrients and
metabolites involved in the homeostasis and physiology of
cells and tissues [15].
The NR superfamily contains transcriptional regulators
that are conserved throughout metazoans, including nema-
todes, insects, and vertebrates [16]. For example, there are
48 and 49 NR members encoded in the human and mouse
genome, respectively. NRs can bind their DNA target sites as
a monomer (e.g., steroidogenic factor (SF-1)), homodimer
(e.g., estrogen receptor (ESR)), or heterodimer (e.g., FXR
and LXR form heterodimers with the retinoid X receptor
RXR). NRs can be ligand-dependent or ligand-independent
transcription factors that activate or repress gene expression
[17]. They play important roles in diverse functions such
as homeostasis, reproduction, development, inﬂammation,
toxicology, and metabolism [18]. NRs are thus key players in
the regulation of complex gene networks.
The known endogenous ligands for NRs consist of a wide
range of chemical structures, such as bile acids, phospho-
lipids, steroid hormones, thyroid hormone, retinoids, and
vitamin D [19]. It is interesting to note that many of these
ligands are derived from cholesterol, suggesting that NRs
have an important role in cholesterol-related metabolism
and pathology. Additionally, it has been suggested that one
and the same NR may have distinct endogenous ligands in
diﬀerent tissues or cell types [20]. This could be particularly
relevant to design therapeutic interventions selectively tar-
geting the availability of one ligand without interfering with
the desired eﬀects of another.
This paper summarizes some recent progress in under-
standing the role of some NRs, including heterodimeric
LXR and FXR and homodimeric ESR, on biliary lipid
secretion and their potential clinical implications for CGD.
The principal features of mechanisms underlying the eﬀect
of NRs on liver and intestine lipid metabolism and transport
and CGD are depicted in Figures 1(a) and 1(b).
3. The LiverX Receptor
The liver X receptors (LXRs), LXRα and LXRβ,a r eo x y s t e r o l
intracellular sensors that regulate key genes related to
sterol, bile acid, and lipid homeostasis [21, 22]. In rodents,
but not in humans, LXR promotes bile acid synthesis by
activating the expression of Cyp7A1, the limiting enzyme of
the neutral bile acid synthesis pathway [23–25]. LXRs are
also known to induce the hepatic expression of cholesterol
and phospholipid eﬄux transporters, including canalicular
ABCG5/ABCG8 [26] as well as ABCA1, a basolateral ABC
transporter of cholesterol and phospholipids [27].
Uppal et al. evaluated the eﬀect of hepatic LXR activation
on lithogenic-diet-fed transgenic mice with constitutively
active expression of LXR [28]. They found an increased
susceptibility of these mice to gallstone disease that corre-
lated with increased biliary concentrations of cholesterol and
phospholipids and decreased biliary bile salt concentrations,
leading to a high cholesterol saturation index in bile. As
expected, hepatic expression of the canalicular transporters
Abcg5/Abcg8 was induced, as well as Abca1 and Cyp7A1,
by administration of LXR agonists in lithogenic-diet-fed
LXR transgenic mice. Moreover, the prolithogenic eﬀect
of LXR activation was abolished in low-density-receptor-
deﬁcient mice. On the other hand, ezetimibe, a cholesterol-
lowering agent that blocks intestinal cholesterol absorption,
had the same eﬀect. These results conﬁrm that hepatic LDL
cholesterol uptake and intestinal cholesterol absorption are
relevant for gallstone disease in this speciﬁc diet-induced
gallstone disease mouse model.
In humans, increased expression of LXR, ABCG5, and
ABCG8 was found in livers of nonobese Chinese gallstone
patients. Moreover, increases in mRNA levels of these genes
signiﬁcantly correlated with biliary cholesterol levels and
saturation [29], suggesting a potential pathogenic role of
LXR activation in human gallstone disease.
Genomewide analysis of gallstone traits in inbred mouse
strains has yielded a susceptibility map of lithogenic (Lith)
loci [30–33]. Interestingly, the Lith1 locus harbors LXRα as
a candidate gene in addition to ABCA11 [33]. However, no
evidence of association between single nucleotide polymor-
phisms (SNPs) for the LXR gene and gallstone susceptibility
was detected in a German population sample [34]. Clearly,
further studies are required to elucidate the relevance of this
hepatic nuclear receptor in the pathogenesis of this disease in
humans.
Although studies evaluating the relevance of intestinal
LXR in gallstone disease are lacking, intestine-speciﬁc LXR
activation decreased cholesterol absorption in transgenic
mice with intestinal expression of constitutively activeJournal of Lipids 3
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Figure 1: (a) Possible molecular mechanisms of action of nuclear receptors at the liver and the small intestine. Cholesterol derived from the
diet as well as from the bile enters the intestine and is absorbed by the enterocytes through NPC1L1 and can be secreted back to the intestinal
lumen by ABCG5/G8. After absorption, cholesterol is incorporated into lipoproteins (Lps), secreted into lymph and blood, and transported
to the liver after triglyceride uptake in peripheral tissues. Bile salts (BSs) are absorbed in the intestine by the ASBT transporter and exit into
the basolateral surface through OSTα/β transporters, among others, reaching the liver via the systemic blood circulation. The hepatic pool
of cholesterol originates from de novo synthesis from acetyl-CoA as well as receptor-mediated endocytosis and/or selective lipid uptake from
Lp. Cholesterol can be secreted into plasma HDL through ABCA1 transporter or by formation and secretion of VLDL (not shown) or into
thebilethroughtheheterodimericABCG5/8transporter.Bileisconstitutedbycholesterol(CH),phospholipids(PLs),andBSs.PLentersthe
biliarycanaliculithroughtheABCB4transporter.BSs,obtainedbyneosynthesisfromcholesterolorbyuptakefromplasma,aresecretedinto
the bile by the ABCB11 transporter. The NRs control metabolism and secretion of lipids at diﬀerent levels: LXR promotes cholesterol eﬄux
from the intestine and from the liver by activation of ABG5/8 and ABCA1 transporters. Also, LXR activates Cyp7A1 leading to an increase in
BS synthesis in the liver. The FXR receptor regulates BS concentration at two diﬀerent levels: promoting the expression of FGF15/19, ILBP,
and OSTα/β transporters in the intestine as well as increasing the expression of ABCB4 and ABC11 transporters and repressing Cyp7A1
expression in the liver. ESRs increase de novo cholesterol synthesis by regulation of HMGCoAR.ASBT: apical sodium bile acid transporter.
OSTα/β: organic solute transporter alpha/beta (b) Cholesterol gallstone formation. An increase in cholesterol and/or a decrease in BS or PL
contents in the bile lead to an increase in the biliary cholesterol saturation index (CSI) triggering cholesterol precipitation into crystals and
ultimately the formation of cholesterol stones within the gallbladder.
LXR [35]. This phenotype correlated with upregulation of
the Abcg5/Abcg8 transporters, which are localized in the
apical membrane in the intestine and mediate cholesterol
eﬄux [26]. Indeed, these transgenic mice fed with ahigh-
cholesterol diet were protected against hepatic cholesterol
accumulation. Thus, in contrast to hepatic LXR activation,
it could be speculated that intestinal LXR activation would
protect from CGD. This opens a window for future thera-
peutic interventions, directed to selective LXR activation in
the intestine, avoiding the side eﬀects of hepatic LXR stimu-
lation, such as increased liver and plasma triglyceride levels.
4.The FarnesoidXReceptor
The farnesoid X receptor (FXR) acts as an intracellular
bile salt sensor [36, 37], induces the expression of ABCB11
and ABCB4, and represses bile salt synthesis by small-
heterodimer-partner-(SHP-) mediated Cyp7A1 inhibition
[36–38]. FXR was also identiﬁed as an attractive candidate
gene for gallstone disease in mice by genomewide inves-
tigation studies [32]. Moreover, lower expression of Fxr
was observed in a mouse strain susceptible for gallstone
formation in comparison with a resistant strain [32].
In addition, mice with isolated hepatic insulin resistance
and increased gallstone susceptibility exhibited increased
bile salt hydrophobicity in bile and partial resistance to
FXR activation by GW4064, a synthetic FXR agonist [39].
More striking, Moschetta et al. [40] found that FXR deﬁ-
ciency in mice conferred a higher susceptibility to CGD
when fed a lithogenic diet. This increased susceptibility
correlated with a higher bile salt hydrophobicity index
and gallbladder mucosal inﬂammation. Also, they found4 Journal of Lipids
a decreased expression of the ABCB4 and ABCB11 trans-
porters involved in biliary phosphatidylcholine and bile
salt secretion. In addition, treatment of lithogenic-diet-
fed gallstone-susceptible mice with FXR agonist GW4064
prevented cholesterol gallstone formation and increased the
expression of ABCB11 and ABCB4 transporters, resulting
in substantially higher bile salt and phospholipid bile
concentrations in gallbladder bile. These results suggest that
modulation of FXR and their downstream targets may be
a good strategy for drug therapy in human CGD; as well
as the modulation of other nuclear receptors has been used
in several other human pathologies [41]. Pharmacological
activation of FXR can selectively increase the secretion
of bile salts and phospholipids, by increasing expression
of the ABCB11 and ABCB4 transporters, allowing the
solubilization of cholesterol in bile.
Some studies in humans have also supported a role of
FXR in gallstone disease. Kovacs et al. showed an association
of a sequence variant in the FXR gene with gallstone preva-
lence in a Mexican cohort [42]. However, no relationship of
this SNP with gallstones was detected in a German cohort,
whereas a trend toward a protective eﬀect of the same SNP
was found in a Chilean population. Interestingly, FXR vari-
ants have been found in Caucasian patients with intrahepatic
cholestasis of pregnancy, a condition known to be associated
with gallstones [43]. In addition, a small study described
the association between reduced hepatic expression of the
PPAR-γ coactivator-1 (PGC-I) and decreased FXR levels in
gallstone patients [44]. Based on this ﬁnding as well as the
role of PGC-1 as a positive activator of FXR expression
[45], the authors speculated that PGC-1 may function
as a protective gene for gallstone disease by increasing
FXR activity. In summary, current data strongly suggest a
relevance of FXR in human gallstone disease point, but more
studies are still required to fully validate this hypothesis.
Besides its role in hepatic lipid homeostasis, FXR activity
should also be considered as a regulator of lipid genes
expressed in the intestine. In this regard, decreased intestinal
expression of FXR and its target genes, ileal lipid-binding
protein (ILBP) and OSTα–OSTβ (all involved in bile acid
transport), has been described in a subgroup of nonobese
gallstone female patients [46, 47]. These ﬁndings suggest a
FXR-dependent defect in the intestine leading to decreased
bile acid absorption and subsequently diminished bile acid
pool. Accordingly, increased bile acid and cholesterol syn-
thesis have been reported in a subgroup of Chilean patients
[48], suggesting that increased intestinal loss of bile acids
may precede gallstone formation.
Another interesting FXR gene target is the ﬁbroblast
growth factor (FGF) 15/19 (mouse and human ortholog,
resp.). FXR induced the expression of FGF15, which acti-
vated a negative feedback on hepatic bile acid neosynthesis
after binding to FGF receptor 4 and impaired gallbladder
emptying after binding to FGF receptor 3 [49]. Interestingly,
ileal FGF19 mRNA levels were diminished in nonobese
gallstone females compared with controls [47]. Further
studies are required to elucidate if FGF19 has a direct role
in the pathogenesis of CGD.
5. Estrogen Receptors
As it is well documented by epidemiological and clinical
studies, CGD prevalence is higher in women than in men
[50–52]. Physiological increase of estrogen levels, in condi-
tions such as human pregnancy, correlates with increased
hepatic secretion of biliary cholesterol and the formation
of a cholesterol-supersaturated bile [53]. Furthermore, oral
contraceptive steroids and conjugated estrogens increase the
risk for CGD [54–56]. Interestingly, estrogens exert their
biological functions through the modulation of two closely
related classical homodimeric nuclear receptors, ESR1 and
ESR2, which are widely expressed in tissues, including the
liver[57–59].Together,thesedatahaveleadtothehypothesis
that estrogens may enhance the risk for CGD by increasing
the functions of the hepatic ESRs [2].
Using gonadectomized gallstone-resistant male or female
AKR mice fed with a lithogenic diet in the presence of
ESR-selective synthetic estrogens has shown a correlation
between gallstone formation and hepatic ESR1 upregulation.
Furthermore, the prolithogenic action of estrogens was
blocked by ESR1-selective antagonists, suggesting that ESR1
is the speciﬁc estrogen receptor pathogenically linked to
gallstone formation. Increased gallstone formation mediated
by estrogen administration in this animal model correlated
with higher biliary cholesterol secretion and the presence of
cholesterol supersaturated bile [59].
High plasma levels of estrogens have been correlated
with augmented activity of the cholesterol biosynthesis
rate-limiting enzyme HMG-CoA reductase in humans and
animals [60, 61], even under high-cholesterol diets. Wang et
al. studied the relevance of hepatic cholesterol neosynthesis
for estrogen-induced gallstone formation in AKR ovariec-
tomyzed mice treated with estrogens and fed with chow
or high-cholesterol diets [61]. They found that estrogens
induced an increase in cholesterol biosynthesis, even in
the presence of a high cholesterol diet. These changes
correlated with increased expression of SREBP2, the key
transcription factor regulator of the HMG-CoA reductase
gene, and also its target genes [61]. There was also an
augmented biliary cholesterol secretion, with an important
increase in the contribution of newly synthesized cholesterol
to biliary cholesterol output. Consistent with accelerated
gallstone formation, a higher lithogenicity of the bile was
found. Moreover, estrogens could also act at the canalicular
membrane by increasing ABCG5/ABCG8 activity [2]. These
results have led to a model in which estrogen induces
cholesterol gallstone formation by promoting cholesterol
biosynthesis through SREBP2 and hepatic biliary cholesterol
secretion.
On the other hand, estrogens can also regulate lipid
and bile salt metabolism through GPR30 receptor activation.
This novel estrogen receptor, a member of the rhodopsin-
like family of G-protein-coupled receptors, is a multipass
membrane protein that has been found in the endoplasmic
reticulum and the cell surface. In normal physiological
conditions,GPR30iswidelyexpressed,withparticularlyhigh
expression reported in heart, lung, liver, intestine, ovary, and
brain [62]. This pattern of expression leads us to proposeJournal of Lipids 5
a possible metabolic role of GPR30 activation not only in
the liver, but also in the small intestine as documented for
L X Ra n dF X Rr e c e p t o r s .I nt h i sr ega r d ,e s tr o g e na ct i v a t i o no f
GPR30 may inﬂuence CGD through nongenomic activation
of rapid kinase signalling pathways.
6. Concluding Remarks
In the past few years, signiﬁcant advances have been made
in understanding the possible molecular mechanisms that
link some nuclear receptors such as LXR, FXR, and ESRs
with CGD. In the liver as well as in the small intestine, these
receptors regulate the expression of key genes involved in
synthesis and transport of cholesterol, bile salts, and phos-
pholipids.Insuchaway,nuclearreceptorsmaymodulatebile
lipid composition and thus the susceptibility to cholesterol
gallstone formation. Even though new insights have been
obtained using animal models, more studies are needed to
establish more deﬁnitively their relevance in human CGD.
The knowledge of nuclear-receptor-dependent mech-
anisms involved in CGD opens a new opportunity for
drug therapy of this disease condition based on modula-
tion of hepatic and/or intestinal cholesterol and bile acid
metabolism. Modulation of intestinal lipid metabolism by
nuclear receptors as well as the role of estrogen receptors
must be explored more deeply to oﬀer new targets for drug
developmentonCGD.Inthisregard,therapeuticapproaches
to CGD would not be limited to the classically liver-related
receptors LXR and FXR.
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